Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.59 |
| ▸ | NPC1 | O15118 | 5/20 | 0.59 |
| ▸ | RAB9A | P51151 | 5/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.59 |
| ▸ | PKM | P14618 | 1/20 | 0.59 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | APP | P05067 | 2/20 | 0.50 |
| ▸ | TP53 | P04637 | 3/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.47 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.47 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.47 |
| ▸ | RELA | Q04206 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | CASP1 | P29466 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29105359 | 0.80 | NPC1 (0.62) | MAPTKDM4ENPC1RAB9ASMN1; SMN2 | |
| SCHEMBL29703893 | 0.80 | MAPT (0.62) | MAPTKDM4ENPC1RAB9ASMN1; SMN2 | |
| SCHEMBL25591566 | 0.80 | MAPT (0.62) | MAPTKDM4ENPC1RAB9ASMN1; SMN2 | |
| SCHEMBL30661712 | 0.80 | NPC1 (0.62) | MAPTKDM4ENPC1RAB9ASMN1; SMN2 | |
| SCHEMBL16835839 | 0.79 | KDM4E (0.53) | MAPTKDM4ENPC1RAB9ASMN1; SMN2 | |
| SCHEMBL24784466 | 0.78 | MAPT (0.57) | MAPTKDM4ENPC1RAB9ASMN1; SMN2 | |
| SCHEMBL2615846 | 0.78 | NPC1 (0.61) | MAPTKDM4ENPC1RAB9ASMN1; SMN2 | |
| SCHEMBL11996731 | 0.78 | SMN1; SMN2 (0.50) | MAPTKDM4ENPC1RAB9ASMN1; SMN2 | |
| SCHEMBL16835888 | 0.78 | CYP11B1 (0.47) | — | |
| SCHEMBL28677979 | 0.77 | APP (0.46) | MAPTKDM4ENPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230305028-A1 | REAGENT COMPOSITION FOR DETECTING ILLICIT DRUGS AND SHEET KIT FOR DETECTING ILLICIT DRUGS COMPRISING SAME | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2023-09-28 | — | — | US | disclosed |
| US-20230080054-A1 | INHIBITORS OF ANOCTAMIN 6 PROTEIN AND USES THEREOF | ILDONG PHARMACEUTICAL CO., LTD. (KR) | 2023-03-16 | — | — | US | disclosed |
| WO-2022195522-A1 | INHIBITORS OF ANO6 AND THEIR USES THEREOF | ILDONG PHARMACEUTICAL CO., LTD. (KR) | 2022-09-22 | — | — | WO | disclosed |
| WO-2022157686-A1 | INHIBITORS OF ANOCTAMIN 6 PROTEIN AND USES THEREOF | ILDONG PHARMACEUTICAL CO., LTD. (KR) | 2022-07-28 | — | — | WO | disclosed |
| WO-2022010089-A1 | REAGENT COMPOSITION FOR DETECTING ILLICIT DRUGS AND SHEET KIT FOR DETECTING ILLICIT DRUGS COMPRISING SAME | 한국생명공학연구원 | 2022-01-13 | — | — | WO | disclosed |
| EP-3448853-B1 | COMPOUNDS FOR MODULATING AQUAPORINS | APOGLYX AB (SE) | 2021-11-17 | — | — | EP | disclosed |
| EP-3448853-B1 | COMPOUNDS FOR MODULATING AQUAPORINS | APOGLYX AB (SE) | 2021-11-17 | — | — | EP | disclosed |
| US-10730865-B2 | Compounds for modulating aquaporins | APOGLYX AB (SE) | 2020-08-04 | — | — | US | disclosed |
| US-10730865-B2 | Compounds for modulating aquaporins | APOGLYX AB (SE) | 2020-08-04 | — | — | US | disclosed |
| US-20190127360-A1 | COMPOUNDS FOR MODULATING AQUAPORINS | APOGLYX AB (SE) | 2019-05-02 | — | — | US | disclosed |
| WO-2012011081-A1 | DERIVATIVES OF OXADIAZOLE AND PYRIDAZINE, THEIR PREPARATION AND THEIR APPLICATION IN THERAPEUTICS | SANOFI (FR) | 2012-01-26 | — | — | WO | disclosed |
| US-8088774-B2 | Anti-inflammatory and protein kinase inhibitor compositions and related methods for downregulation of detrimental cellular responses and inhibition of cell death | NORTHWESTERN UNIVERSITY (US) | 2012-01-03 | — | — | US | disclosed |
| US-8088774-B2 | Anti-inflammatory and protein kinase inhibitor compositions and related methods for downregulation of detrimental cellular responses and inhibition of cell death | NORTHWESTERN UNIVERSITY (US) | 2012-01-03 | — | — | US | disclosed |
| US-20110046127-A1 | Imidazopyridazines for Use as Protein Kinase Inhibitors | CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS (CNIO) (ES) | 2011-02-24 | — | — | US | disclosed |
| US-7888357-B2 | Anti-inflammatory and protein kinase inhibitor compositions and related methods for downregulation of detrimental cellular responses and inhibition of cell death | NORTHWESTERN UNIVERSITY (US) | 2011-02-15 | — | — | US | disclosed |
| US-7888357-B2 | Anti-inflammatory and protein kinase inhibitor compositions and related methods for downregulation of detrimental cellular responses and inhibition of cell death | NORTHWESTERN UNIVERSITY (US) | 2011-02-15 | — | — | US | disclosed |
| US-20100317665-A1 | Anti-Inflammatory And Protein Kinase Inhibitor Compositions And Related Methods For Downregulation Of Detrimental Cellular Responses And Inhibition Of Cell Death | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-12-16 | — | — | US | disclosed |
| US-20100317665-A1 | Anti-Inflammatory And Protein Kinase Inhibitor Compositions And Related Methods For Downregulation Of Detrimental Cellular Responses And Inhibition Of Cell Death | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-12-16 | — | — | US | disclosed |
| EP-2217601-A1 | IMIDAZOPYRIDAZINES FOR USE AS PROTEIN KINASE INHIBITORS | Centro Nacional de Investigaciones Oncológicas (CNIO) (ES) | 2010-08-18 | — | — | EP | disclosed |
| WO-2009060197-A1 | IMIDAZOPYRIDAZINES FOR USE AS PROTEIN KINASE INHIBITORS | CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS (CNIO) (ES) | 2009-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10730865-B2 | Compounds for modulating aquaporins | AQP1, AQP4, AQP3 | MAPT 2603/4885KDM4E 4131/4885NPC1 96/4885 |
| US-20190127360-A1 | COMPOUNDS FOR MODULATING AQUAPORINS | AQP1, AQP4, AQP3 | MAPT 2603/4885KDM4E 4131/4885NPC1 96/4885 |
| US-20230080054-A1 | INHIBITORS OF ANOCTAMIN 6 PROTEIN AND USES THEREOF | ANO1, ANO2, CACYBP | MAPT 3044/4885KDM4E 3252/4885NPC1 2582/4885 |
| US-20100317665-A1 | Anti-Inflammatory And Protein Kinase Inhibitor Compositions And Related Methods For Downregulation Of Detrimental Cellular Responses And Inhibition Of Cell Death | CASP2, CASP1, DAPK2 | MAPT 1672/4885KDM4E 1828/4885NPC1 3563/4885 |
| US-20230305028-A1 | REAGENT COMPOSITION FOR DETECTING ILLICIT DRUGS AND SHEET KIT FOR DETECTING ILLICIT DRUGS COMPRISING SAME | CYP3A5, GABRA5, CYP3A7 | MAPT 1458/4885KDM4E 728/4885NPC1 2362/4885 |
| US-20110046127-A1 | Imidazopyridazines for Use as Protein Kinase Inhibitors | PIM1, PIM3, PIM2 | MAPT 3988/4885KDM4E 698/4885NPC1 3092/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.